#United States #Pittsburgh #PANTHERx #Rhythm Pharmaceuticals #IMCIVREE

PANTHERx® Rare Selected as Exclusive Pharmacy for IMCIVREE®

In a significant advancement in patient care for rare diseases, PANTHERx® Rare Pharmacy has been chosen by Rhythm Pharmaceuticals, Inc. as the exclusive specialty pharmacy in the U.S. for the expanded indication of IMCIVREE® (setmelanotide). This partnership aims to enhance treatment accessibility for both adults and children aged four and older suffering from acquired hypothalamic obesity, a rare and complex condition characterized by serious weight gain due to hypothalamic injury.

Understanding Acquired Hypothalamic Obesity

Acquired hypothalamic obesity results from damage to the hypothalamus, often following the growth of tumors or due to injuries such as trauma or stroke. Patients typically experience significant challenges, including increased hunger and decreased energy expenditure, which makes weight management particularly difficult. Consequently, the condition can severely impact the patient's quality of life, necessitating targeted therapy options like IMCIVREE®.

The Role of PANTHERx® Rare

PANTHERx® Rare has established a reputation as a leader in the domain of rare disease care. Utilizing its innovative RxARECARE® model, it provides comprehensive support to patients, caregivers, and healthcare providers. Through personalized case management, proactive educational resources, and navigational assistance for insurance and financial matters, PANTHERx works diligently to minimize the complexities associated with rare disease treatments.

Bansi Nagji, CEO of PANTHERx Rare, emphasized the importance of this new therapy, stating, "This new indication for IMCIVREE marks an important scientific milestone for individuals and families affected by acquired hypothalamic obesity, a highly complex disease with historically limited therapeutic options." He also acknowledged the privilege of collaborating closely with Rhythm Pharmaceuticals to supply essential clinical support for patients undergoing treatment.

A Longstanding Relationship with Rhythm Pharmaceuticals

PANTHERx has been the dedicated pharmacy provider for IMCIVREE since 2020, assisting those with obesity linked to Bardet-Biedl Syndrome and other genetic deficiencies. This new indication broadens PANTHERx’s commitment to specialized care in the field of rare conditions and reinforces its role as a dependable ally for patients facing challenging health obstacles.

Conclusion

As PANTHERx expands its services to include the management of acquired hypothalamic obesity, it continues to focus on hyper-personalizing healthcare experiences. This strategy involves fostering close relationships with patients and working closely with pharmaceutical companies to ensure that individuals receive the comprehensive support they deserve in their healthcare journeys. Since its inception in 2011, PANTHERx has built an impressive reputation in the U.S. as the largest independent rare pharmacy, blending responsiveness with innovative solutions to patient care.

For more detailed inquiries, visit PANTHERx Rare’s official website or contact their support team.